SUMAVEL DosePro - Resources

Title Image:

SUMAVEL DosePro Savings Program

Automatic Rx savings*
- 65% of pharmacies offer automatic savings, including Walmart, CVS, and Rite Aid
- No card required. Patients automatically receive up to $100 off every
  SUMAVEL^® DosePro^® prescription after they pay a $35 co-pay

Pharmacists requesting help with claim processing should call 1-800-388-2316. Pharmacists enquiring about enrolling in the program should call 1-800-215-9392. Click here for a list of participating pharmacies.

$15 Co-pay Card^†
- Patients will receive up to $100 off their SUMAVEL DosePro prescription after they pay a $15 co-pay
- Available from your sales representative or click here to download a coupon
- Can be used for up to 6 prescription fills

Patients with additional questions about the $15 co-pay card should call 1-877-343-6451, and press zero (0) to speak to a Trial Card associate. Pharmacists with additional questions about the $15 co-pay card should call 1-877-343-6456.

*Eligibility and Restrictions: No claims paid by government-sponsored insurance plans including Medicare, Medicaid, federal, state, or patient pharmaceutical assistance. Patients must be between the ages of 18 and 64. No pharmacies in states that prohibit the offering of co-pay assistance at the point of dispensing. No cash claims.

^†Subject to eligibility. Both insured and noninsured patients are eligible to participate in this program, excluding federal Medicare, Medicaid, and other federal or state-funded programs. Patients must be 18 years or older to participate.

Fill out your information below to receive a call from a Sales Representative:

*First name
*Last name
Institution/Clinic
*Specialty
Street Address 1
Street Address 2
*State
*ZIP code
*Phone
*Email

*Required fields

If you have any medical inquiries, please call 1-866-ZOGENIX

INDICATION and IMPORTANT LIMITATIONS

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine and should not be administered intravenously. SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been established. For a given attack, if a patient does not respond to the first dose of SUMAVEL DosePro, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose.

IMPORTANT SAFETY INFORMATION

SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic bowel disease and in patients with other significant underlying cardiovascular diseases or known hypersensitivity to sumatriptan. SUMAVEL DosePro should not be given to patients in whom unrecognized coronary artery disease is predicted by the presence of risk factors without a prior cardiovascular evaluation.

Serious cardiovascular events, including death, have been reported when taking sumatriptan, including patients with no findings of cardiovascular disease. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low. Cerebrovascular events, some fatal, have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cerebrovascular events were primary, sumatriptan having been administered in the incorrect belief the symptoms experienced were a consequence of migraine when they were not. It is important to advise patients not to administer SUMAVEL DosePro if a headache being experienced is atypical.

Do not use SUMAVEL DosePro and any ergotamine-containing or ergot-type medication within 24 hours of each other; do not use SUMAVEL DosePro and another 5-HT1 agonist (e.g. triptan) within 24 hours of each other (with the exception of a single dose of another sumatriptan product, provided the doses are separated by at least 1 hour). SUMAVEL DosePro is not generally recommended for use with MAO-A inhibitors. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with SUMAVEL DosePro, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy only if the potential benefit justifies the potential risk.

In controlled clinical trials with sumatriptan injection, the most common adverse reactions were injection site reactions, tingling, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, feeling of tightness, numbness, feeling strange, tight feeling in head, flushing, tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort, dizziness/vertigo, drowsiness/sedation and headache.

By clicking OK, you will leave the SUMAVEL DosePro website. Zogenix, Inc. does not review the information on this website for content, accuracy, completeness or compliance with any applicable statute, rule or regulation.

OK Cancel

The information in this section is intended for healthcare professionals in the United States and is not intended for the general public.

Please confirm below that you are a healthcare professional.

OK Cancel